LSD1-IN-13

• UNSPSC Description:

  LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC50 of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC50 of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines[1].

• Target Antigen:

  Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lsd1-in-13.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(N1CCC2=C1C=CC([C@H]3[C@H](NCC4CCNCC4)C3)=C2)(C5=CC=CC=C5)=O

• Molecular Weight:

  411.56

• References & Citations:

  [1]Li C, et al. Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors. J Med Chem. 2022 Mar 10;65(5):4335-4349.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2170212-33-4